End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
65.37 CNY | -0.18% | +0.26% | +24.87% |
Mar. 18 | China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6% | MT |
Mar. 18 | Xiamen Amoytop Biotech Gets Nod to Market Hepatitis Drug; Shares Up 4% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 35.27 and 25.76 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.87% | 3.68B | - | ||
-4.89% | 85.08B | A- | ||
+2.11% | 40.14B | A- | ||
-25.74% | 28.37B | B- | ||
+51.96% | 24.07B | A | ||
-6.17% | 17.24B | C | ||
-31.09% | 13.85B | B | ||
-6.58% | 12.29B | D+ | ||
-16.04% | 11.95B | B- | ||
-4.19% | 8.02B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688278 Stock
- Ratings Xiamen Amoytop Biotech Co., Ltd.